Published in Medical Letter on the CDC and FDA, June 5th, 2005
"We are pleased to bring this new and exciting diagnostic tool for monitoring mesothelioma before the FDA for review," said Paul Touhey, president and COO for FDI. "MESOMARK further demonstrates FDI's commitment to deliver novel, innovative, and noninvasive technologies that help patients and physicians better manage cancer."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.